降压治疗患者的原发性醛固酮增多症筛查方法
原发性醛固酮增多症(PA)仍被大幅忽视,导致显著的死亡与疾病负担。筛查率低的主要原因是降压治疗可能干扰醛固酮与肾素水平,进而混淆醛固酮与肾素比值(ARR)这一常规筛查试验的解读。本综述评估降压治疗对PA筛查试验的影响,并提出实用的解读方法。
要点
- PA仍被大幅忽视,尽管已有关于醛固酮心血管危害的临床与转化研究及多部指南和共识。
- 筛查率低的主因是降压治疗可能干扰醛固酮和肾素水平,混淆ARR筛查试验的解读。
- 通常需撤除影响肾素-血管紧张素-醛固酮系统的药物并替换为非干扰药物,但许多情况下不停药也能可靠解读筛查试验。
核心结论
- 本综述评估降压治疗对PA筛查试验的影响,并建议实用的解读方法。
研究设计与样本
- 综述,评估降压治疗对原发性醛固酮增多症筛查试验的影响。
主要发现
- PA仍被大幅忽视,导致显著的死亡与疾病负担。
- 筛查率低的主要原因是降压治疗可能干扰醛固酮和肾素水平,从而混淆醛固酮与肾素比值的解读。
- 通常需撤除影响肾素-血管紧张素-醛固酮系统的治疗并替换为非干扰药物。
- 许多情况下即使不中断此类治疗,筛查试验仍可可靠解读。
临床怎么用
- 作者建议对降压治疗患者筛查PA时评估降压治疗对筛查试验的影响,并采用实用的解读方法。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Primary aldosteronism (PA) is a condition that is still largely overlooked, resulting in a considerable burden of mortality and morbidity. This is despite decades of clinical and translational research on the deleterious effects of aldosterone on the cardiovascular system and the publication of several guidelines and consensuses on its diagnosis and treatment. One of the main reasons for the low rate of testing is the difficulty of screening patients on antihypertensive therapy that potentially interferes with aldosterone and renin levels and thus confound the interpretation of the aldosterone to renin ratio, the accepted and conventionally used screening test. To avoid interference, usually the therapies that affect the renin-angiotensin aldosterone system are withdrawn and substituted with noninterfering medications. However, in many cases the screening test can be confidently interpreted even when such therapies are not discontinued. In this review, we will evaluate the effects of antihypertensive therapies on the screening test for PA and suggest a practical approach for its interpretation.
引用
- Mulatero P, Bertello C, Veglio F, et al. Approach to the Patient on Antihypertensive Therapy: Screen for Primary Aldosteronism. J Clin Endocrinol Metab. 2022. PMID: 35964152. doi:10.1210/clinem/dgac460
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。